Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jennifer J. Furin, M.D., Ph.D.

Co-Author

This page shows the publications co-authored by Jennifer Furin and Jaime Bayona.
Connection Strength

0.677
  1. Programmatic management of multidrug-resistant tuberculosis: models from three countries. Int J Tuberc Lung Dis. 2011 Oct; 15(10):1294-300.
    View in: PubMed
    Score: 0.118
  2. Expanding global HIV treatment: case studies from the field. Ann N Y Acad Sci. 2008; 1136:12-20.
    View in: PubMed
    Score: 0.091
  3. Treatment of multidrug-resistant tuberculosis during pregnancy: a report of 7 cases. Clin Infect Dis. 2003 Apr 15; 36(8):996-1003.
    View in: PubMed
    Score: 0.067
  4. Peripheral neuropathy associated with treatment for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2003 Apr; 7(4):347-53.
    View in: PubMed
    Score: 0.067
  5. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2001 Jul; 5(7):648-55.
    View in: PubMed
    Score: 0.059
  6. Effect of administering short-course, standardized regimens in individuals infected with drug-resistant Mycobacterium tuberculosis strains. Eur J Clin Microbiol Infect Dis. 2000 Feb; 19(2):132-6.
    View in: PubMed
    Score: 0.054
  7. Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality. PLoS One. 2013; 8(3):e58664.
    View in: PubMed
    Score: 0.033
  8. Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. Clin Infect Dis. 2013 Mar; 56(6):770-6.
    View in: PubMed
    Score: 0.033
  9. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008 Aug 07; 359(6):563-74.
    View in: PubMed
    Score: 0.024
  10. Long-term follow-up for multidrug-resistant tuberculosis. Emerg Infect Dis. 2006 Apr; 12(4):687-8.
    View in: PubMed
    Score: 0.021
  11. Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB. Int J Tuberc Lung Dis. 2006 Mar; 10(3):290-6.
    View in: PubMed
    Score: 0.020
  12. Community-based treatment of multidrug-resistant tuberculosis in Lima, Peru: 7 years of experience. Soc Sci Med. 2004 Oct; 59(7):1529-39.
    View in: PubMed
    Score: 0.018
  13. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet. 2004 Feb 07; 363(9407):474-81.
    View in: PubMed
    Score: 0.018
  14. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med. 2003 Jan 09; 348(2):119-28.
    View in: PubMed
    Score: 0.016
  15. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2000 Feb; 4(2):108-14.
    View in: PubMed
    Score: 0.013
  16. Management of MDR-TB in resource-poor countries. Int J Tuberc Lung Dis. 1999 Aug; 3(8):643-5.
    View in: PubMed
    Score: 0.013
  17. The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis. 1998 Nov; 2(11):869-76.
    View in: PubMed
    Score: 0.012
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.